| By Lonza |
| Monday, 21 June 2010 |
 |
Lonza, a leader in biopharmaceutical development services and contract manufacturing, is launching a new set of immunogenicity, stability and protein engineering services to benefit customers. The newly integrated Applied Protein Services platform is effective at improving the quality, safety, efficacy and manufacturability of antibodies, therapeutic proteins and vaccines.
|
|
"Development risk and attrition rates remain two of the greatest challenges to a successful biopharmaceutical program," said Philippe Stas, Head of Lonza's Applied Protein Services group. "Our
|
|
|
newly integrated preclinical services help mitigate both aspects by providing a window into the future of a biologic, which supports the successful selection and optimization as well as the early process development of promising drug candidates."
The Applied Protein Services platform complements Lonza's well-established, industry-leading process development and manufacturing capabilities while advancing the company's efforts to incorporate Quality by Design (QbD) principles.
Customer Services Available
Epibase & Epibase IV
Computer-based and cellular immunoprofiling |
|
for lead selection, lead comparison, optimization and surveillance
Tripole
Technology platform for protein structure analysis, modeling, engineering, deimmunization and antibody optimization
AggreSolve
Technology platform to resolve protein aggregation and stability challenges
|
|
|
